Hint mode is switched on Switch off
For swift navigation between sections

Assertio Therapeutics
LEI 549300L2A9NTF1JVDP20

Liquidated
Successor company: Assertio Holdings
Organization name
Assertio Therapeutics, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
  • M/S&P/F
    *** / *** / ***
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Quotes

Request sent
Access denied
Quotes provided by information providers are indicative in nature

Profile

As a result of the Assertio Reorganization, Assertio Holdings became the successor issuer to Assertio Therapeutics, Inc. Assertio Therapeutics, Inc., formerly Depomed Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States.

Awards

Documentation

Stocks

Latest issues

Public debt by currencies

Codes

  • LEI
    549300L2A9NTF1JVDP20
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001005201
Registration is required to get access.